FIXED DOSE FORMULATIONS
Herein disclosed are novel compositions comprising: Bempedoic acid and Bempedoic acid and Ezetimibe, kits, methods of using and processes for making said novel compositions. Notably, the formulations herein provide pharmaceutical compositions having excellent stability and release properties for both drug products. These improved formulations are useful in the treatment and prevention of cardiovascular disease.
1 . A pharmaceutical composition comprising:
180 mg Bempedoic acid;
10 mg Ezetimibe;
4 mg colloidal silicon dioxide;
4 mg magnesium stearate;
12 mg hydroxypropyl cellulose—low substituted;
1 mg Povidone;
75 mg Lactose monohydrate;
2 mg sodium lauryl sulfate;
60.6 mg microcrystalline cellulose; and
27 mg sodium starch glycolate.
2 .- 4 . (canceled)
5 . The pharmaceutical composition of claim 1 , wherein the composition is in the form of a tablet and further comprises a polyvinyl alcohol (PVA) based coating; and wherein the coating comprises: polyvinyl alcohol (PVA), glycerol monocaprylocaprate type 1, sodium lauryl sulfate, titanium dioxide and talc.
6 . (canceled)
7 . The pharmaceutical composition of claim 1 , wherein the composition has a bulk density of at least 0.25 gm/ml and no more than 0.55 gm/ml.
8 . The pharmaceutical composition of claim 1 , wherein the composition has a Carr's Index of at least 10 and no more than 30.
9 . The pharmaceutical composition of claim 1 , wherein the granules of the composition have an angle of repose of at least 200 and no more than 45°.
10 . A granulated composition comprising 180 mg Bempedoic acid;
3.5 mg colloidal silicon dioxide;
9.6 mg microcrystalline cellulose; and
12 mg hydroxypropyl cellulose—low substituted.
11 .- 12 . (canceled)
13 . The composition of claim 10 , wherein the composition has a Carr's Index of at least 10 and no more than 30.
14 . The composition of claim 10 , wherein the granules of the composition have an angle of repose of at least 200 and no more than 45°.
15 . The composition of claim 10 , wherein the Bempedoic acid is present in an amount of at least 50% and no more than 95% by weight of the total formulation.
16 . (canceled)
17 . A bilayer tablet comprising Bempedoic acid and Ezetimibe, wherein the first layer composition comprises:
Ezetimibe granulated with a pharmaceutically acceptable excipient;
and wherein the second layer composition comprises:
Bempedoic acid granulated with colloidal silicon dioxide and a pharmaceutically acceptable excipient; and
wherein the first and second compositions comprise:
180 mg Bempedoic acid;
10 mg Ezetimibe;
4 mg colloidal silicon dioxide;
4 mg magnesium stearate;
12 mg hydroxypropyl cellulose—low substituted;
1 mg Povidone;
75 mg Lactose monohydrate;
2 mg sodium lauryl sulfate;
60.6 mg microcrystalline cellulose; and
27 mg sodium starch glycolate.
18 . The bilayer tablet of claim 17 , wherein the Friability of the tablet is at least 0.01% and no more than 0.1%.
19 . The bilayer tablet of claim 17 , wherein the first layer composition is at least 0.1% and no more than 23% by weight of the total tablet and the second layer composition is at least 0.1% and no more than 74% by weight of the total tablet.
20 . (canceled)